Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

China's Plan to Exempt More Devices From Trials Will Save Companies Effort And Cost

This article was originally published in SRA

Executive Summary

China's Food and Drug Administration is inviting feedback on a new batch of medium- and high-risk medical devices that it intends to exempt from having to undergo local clinical trials1. The agency's proposal, if adopted, would make it much easier and less costly for companies that want to place these devices on the Chinese market2.


Related Content

China's Medtech Regulatory Reforms Yet To Enter Steady Path